ALK-Abelló Logo

ALK-Abelló

Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.

ALK | CO

Overview

Corporate Details

ISIN(s):
DK0061802139
LEI:
529900SGCREUZCZ7P020
Country:
Denmark
Address:
Bøge Alle 6-8, 2970 Hørsholm
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ALK-Abelló is a global pharmaceutical company specializing in the research, development, and manufacturing of allergy immunotherapy (AIT) products. A pioneer in the field for over a century, the company focuses on creating treatments that address the underlying cause of allergies, rather than merely managing symptoms. Its portfolio encompasses a range of evidence-based AIT products, including tablets, drops, and injections, as well as emergency treatments for severe allergic reactions like anaphylaxis. ALK's primary therapeutic areas are respiratory allergies, food allergies, and anaphylaxis. The company is committed to scientific innovation and expanding access to its solutions, such as needle-free adrenaline treatments, to improve the lives of people with allergies worldwide.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-12 17:17
Regulatory News Service
Danish 102.5 KB
2025-11-12 17:17
Earnings Release
Danish 3.3 KB
2025-11-12 17:17
Regulatory News Service
English 104.1 KB
2025-11-12 17:17
Earnings Release
English 2.8 KB
2025-09-17 09:44
M&A Activity
Danish 174.5 KB
2025-09-17 09:44
M&A Activity
Danish 10.0 KB
2025-09-17 09:44
M&A Activity
English 8.9 KB
2025-09-17 09:44
M&A Activity
English 274.6 KB
2025-08-21 07:30
Earnings Release
English 11.5 KB
2025-08-21 07:30
Interim Report
English 505.8 KB
2025-08-21 07:30
Interim Report
English 505.8 KB
2025-08-21 07:30
Earnings Release
English 12.0 KB
2025-08-12 14:45
Earnings Release
Danish 103.0 KB
2025-08-12 14:45
Earnings Release
Danish 3.7 KB
2025-08-12 14:45
Earnings Release
English 108.6 KB

Automate Your Workflow. Get a real-time feed of all ALK-Abelló filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ALK-Abelló

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ALK-Abelló via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Crinetics Pharmaceuticals, Inc. Logo
Develops novel therapeutics for rare endocrine diseases and related tumors.
United States of America
CRNX
CRISPR Therapeutics AG Logo
Develops transformative CRISPR gene-based medicines for diseases like sickle cell.
United States of America
CRSP
Crossject Logo
Develops needle-free auto-injectors for rapid drug delivery in medical emergencies.
France
ALCJ
CTC BIO, INC. Logo
Develops pharmaceuticals and feed additives for human and animal health using fermentation tech.
South Korea
060590
Cue Biopharma, Inc. Logo
Develops injectable biologics to selectively activate T cells for oncology & autoimmune disease.
United States of America
CUE
Cullinan Therapeutics, Inc. Logo
Developing differentiated immune-modulating therapies for cancer and autoimmune diseases.
United States of America
CGEM
CUMBERLAND PHARMACEUTICALS INC Logo
Acquires and commercializes branded medicines for acute care, gastroenterology, and oncology.
United States of America
CPIX
Cuorips Inc. Logo
Develops iPS cell therapies, like a cardiomyocyte sheet for severe heart failure.
Japan
4894
Cuprina Holdings (Cayman) LTD Logo
Biomedical firm specializing in Maggot Debridement Therapy for wound care in Singapore & Hong Kong.
United States of America
CUPR
curacle co., ltd. Logo
Developing drugs for intractable diseases like diabetes caused by vascular damage and aging.
South Korea
365270

Talk to a Data Expert

Have a question? We'll get back to you promptly.